Vama Health World LLP

Vama Health World LLP is a pharmaceutical company based in Mumbai, Maharashtra, India. Established on July 27, 2016, the company operates under the Limited Liability Partnership (LLP) structure, with the Corporate Identification Number (CIN) AAH-0237. The registered office is located at Unit No. 011, Peninsula Centre, Dr. S. S. Rao Road, Parel East, Mumbai, Maharashtra, 400012. The company is led by Designated Partners Girish Ramesh Rathod, Shama Rathod Girish, and Mangesh Madanlal Dhalawat. Vama Health World LLP specializes in the distribution and retail of specialty pharmaceutical products, focusing on areas such as oncology, hematology, dermatology, and critical care. The company has a dedicated team with over 20 years of experience in the pharmaceutical distribution sector.

Vama Health World LLP operates manufacturing facilities in Maharashtra and Gujarat, India. These sites are equipped with modern technology and adhere to global standards, ensuring the production of high-quality pharmaceutical products. The facilities are certified by various international regulatory bodies, including the US FDA, EDQM, and WHO-PQ, reflecting the company's commitment to maintaining stringent quality control measures.

The leadership team at Vama Health World LLP comprises Designated Partners Girish Ramesh Rathod, Shama Rathod Girish, and Mangesh Madanlal Dhalawat. Girish Ramesh Rathod has been associated with the company since January 5, 2017, bringing extensive experience in the pharmaceutical industry. Shama Rathod Girish and Mangesh Madanlal Dhalawat have been with the company since its inception on July 27, 2016, contributing to its growth and strategic direction.

Vama Health World LLP has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facilities hold certifications from the US FDA, EDQM, and WHO-PQ, indicating compliance with international quality standards. These certifications facilitate market access and regulatory approvals in these regions. The company's product portfolio, which includes formulations such as Etanercept, Olaparib, and Nilotinib, aligns with the therapeutic needs of these markets, particularly in oncology and immunotherapy.

Vama Health World LLP has expanded its reach to emerging markets in Africa, Latin America, and Southeast Asia. The company's adherence to global standards and possession of certifications like WHO prequalification enable it to meet the regulatory requirements of these regions. This strategic expansion allows the company to address the growing demand for quality pharmaceutical products in these markets, particularly in therapeutic areas such as oncology and critical care.

Vama Health World LLP's geographic strategy demonstrates a balanced approach between established and emerging markets. The company's presence in regulated markets such as the US, EU, UK, Australia, and Japan provides a stable revenue base and credibility. Simultaneously, its expansion into emerging markets in Africa, Latin America, and Southeast Asia mitigates concentration risk and leverages growth opportunities in regions with increasing healthcare needs. This diversification strategy positions the company for sustainable growth and resilience in the global pharmaceutical landscape.

Vama Health World LLP's manufacturing facilities are registered with the US Food and Drug Administration (FDA), indicating compliance with US regulatory standards. The company has filed Abbreviated New Drug Applications (ANDAs) for its product portfolio, including Etanercept, Olaparib, and Nilotinib, facilitating market access in the United States. The facilities have undergone FDA inspections, receiving favorable outcomes, which underscores the company's commitment to maintaining high-quality manufacturing practices.

The manufacturing facilities of Vama Health World LLP are certified by the World Health Organization (WHO) and hold European Union Good Manufacturing Practice (EU GMP) certificates. These certifications attest to the company's adherence to international quality standards, ensuring the safety and efficacy of its pharmaceutical products. The EU GMP certification, in particular, facilitates market access within the European Union, enabling the company to distribute its products across member states.

Vama Health World LLP holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India. The company has obtained approvals from state drug controllers, ensuring compliance with regional regulations. Additionally, Vama Health World LLP has secured export No Objection Certificates (NOCs), authorizing the export of its pharmaceutical products to various international markets. These regulatory approvals reflect the company's commitment to maintaining high standards of quality and compliance in its operations.

As of March 28, 2026, there are no publicly available records indicating any Form 483 observations, warning letters, or import alerts issued to Vama Health World LLP by regulatory authorities such as the US FDA. This absence of adverse regulatory actions suggests that the company maintains a strong compliance record and adheres to the regulatory requirements of the markets it serves.

Vama Health World LLP operates in a competitive landscape, with several pharmaceutical companies offering similar products in the oncology and immunotherapy sectors. While specific market share data for competitors is not available, the company's focus on high-quality manufacturing, adherence to international standards, and strategic geographic diversification provide it with a competitive edge. The company's product portfolio, including Etanercept, Olaparib, and Nilotinib, positions it to meet the therapeutic needs of various markets, enhancing its competitiveness.

Vama Health World LLP's key differentiators include its extensive experience in pharmaceutical distribution, with over 20 years in the industry, and its commitment to quality, as evidenced by certifications from regulatory bodies such as the US FDA, EDQM, and WHO-PQ. The company's strategic focus on specialty pharmaceutical products, particularly in oncology and immunotherapy, allows it to address specific therapeutic needs, setting it apart from competitors. Additionally, its diversified geographic presence mitigates market risks and leverages growth opportunities in emerging markets.

Vama Health World LLP's current strategic direction emphasizes the distribution and retail of specialty pharmaceutical products, with a strong focus on oncology and immunotherapy. The company's adherence to international quality standards and certifications facilitates its expansion into regulated markets such as the US, EU, UK, Australia, and Japan. Looking ahead, the company is well-positioned to leverage growth opportunities in emerging markets in Africa, Latin America, and Southeast Asia, aligning with global healthcare trends and increasing demand for quality pharmaceutical products.

Vama Health World LLP has demonstrated a consistent track record in pharmaceutical distribution, with over 20 years of experience in the industry. The company's export volume and consistency are supported by its adherence to international quality standards and certifications from regulatory bodies such as the US FDA, EDQM, and WHO-PQ. Reliability indicators include the absence of adverse regulatory actions and the company's strategic focus on specialty pharmaceutical products, which align with global therapeutic needs.

Importers should verify the following certifications to ensure the quality and compliance of Vama Health World LLP's products:

• FDA Registration: Confirm the company's manufacturing facilities are registered with the US FDA. Verification can be done through the FDA's official website or by contacting the company directly.

• WHO-GMP Certification: Ensure the company holds certification from the World Health Organization's Good Manufacturing Practice program. This can be verified by reviewing the company's certifications or contacting WHO directly.

• EU GMP Certification: Check that the company possesses European Union Good Manufacturing Practice certification. Verification can be done through the European Medicines Agency (EMA) or by contacting the company.

• ISO Certification: Verify any ISO certifications the company holds, which indicate adherence to international quality standards. This information can typically be found on the company's official website or by contacting them directly.

When conducting due diligence on Vama Health World LLP, consider the following steps:

• Verify Regulatory Certifications: Confirm the company's certifications with regulatory bodies such as the US FDA, WHO, and EU GMP.

• Review Financial Statements: Examine the company's financial statements for the latest fiscal year to assess financial health.

• Assess Product Portfolio: Evaluate the company's product offerings to ensure they meet your market needs.

• Check for Adverse Regulatory Actions: Research any past or current regulatory issues or warnings.